Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vismodegib for idiopathic pulmonary fibrosis (phase II, Germany)
2014-000963-42Phase 2Terminated
- Sponsor
- Roche
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Vismodegib with Placebo (2 arms). Primary endpoint: Change in pulmonary function (FVC% predicted). Started Aug 2014; status: terminated.
02
Drugs
vismodegib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2014-000963-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000963-42.